Market capitalization | €5.20b |
Enterprise Value | €5.46b |
P/E (TTM) P/E ratio | 19.89 |
EV/FCF (TTM) EV/FCF | 30.05 |
EV/Sales (TTM) EV/Sales | 2.65 |
P/S ratio (TTM) P/S ratio | 2.52 |
P/B ratio (TTM) P/B ratio | 2.48 |
Dividend yield | 1.89% |
Last dividend (FY23) | €1.10 |
As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.
16 Analysts have issued a Carl Zeiss Meditec forecast:
16 Analysts have issued a Carl Zeiss Meditec forecast:
Mar '24 |
+/-
%
|
||
Revenue | 2,062 2,062 |
2%
2%
|
|
Gross Profit | 1,161 1,161 |
1%
1%
|
|
EBITDA | 374 374 |
16%
16%
|
EBIT (Operating Income) EBIT | 299 299 |
19%
19%
|
Net Profit | 261 261 |
6%
6%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Carl Zeiss Meditec AG engages in the development, manufacture, and marketing of medical devices. It operates through the Ophthalmic Devices and Microsurgery business segments. The Ophthalmic Devices segment includes intraocular lenses, surgical visualization solutions, and medical laser and diagnostic systems. The Microsurgery segment offers surgical microscopes and visualization solutions for neuro, ear, nose, and throat surgery, as well as the activities in the field of intraoperative radiotherapy. The company was founded on October 4, 1995 and is headquartered in Jena, Germany.
Head office | Germany |
CEO | Markus Weber |
Employees | 4,823 |
Founded | 1995 |
Website | www.zeiss.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.